Efficacy of upadacitinib for moderate-to-severe atopic dermatitis: analysis of time spent in skin clearance response states from the Measure Up 1, Measure Up 2 and Heads Up studies

被引：0
|
作者：
Blauvelt, Andrew [1 ]
Silverberg, Jonathan, I [2 ]
Calimlim, Brian M. [3 ]
Liu, Yingyi [3 ]
Platt, Andrew [3 ]
Thyssen, Jacob P. [4 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] George Washington Univ, Dept Dermatol, Sch Med & Hlth Sci, Washington, DC USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Bispebjerg Hosp, Dept Dermatol, Copenhagen, Denmark
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
upadacitinib; dupilumab; atopic dermatitis; skin clearance; EASI;
D O I：
10.1093/bjd/ljac140.047
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
355
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double- blind, randomised controlled phase 3 trials
    Guttman-Yassky, Emma
    Teixeira, Henrique D.
    Simpson, Eric L.
    Papp, Kim A.
    Pangan, Aileen L.
    Blauvelt, Andrew
    Thaci, Diamant
    Chu, Chia-Yu
    Hong, H. Chih-Ho
    Katoh, Norito
    Paller, Amy S.
    Calimlim, Brian
    Gu, Yihua
    Hu, Xiaofei
    Liu, Meng
    Yang, Yang
    Liu, John
    Tenorio, Allan R.
    Chu, Alvina D.
    Irvine, Alan D.
    LANCET, 2021, 397 (10290): : 2151 - 2168
  • [32] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
    Silverberg, Jonathan I.
    Gooderham, Melinda J.
    Paller, Amy S.
    Deleuran, Mette
    Bunick, Christopher G.
    Gold, Linda F. Stein
    Hijnen, Dirkjan
    Calimlim, Brian M.
    Lee, Wan-Ju
    Teixeira, Henrique D.
    Hu, Xiaofei
    Zhang, Shiyu
    Yang, Yang
    Grada, Ayman
    Platt, Andrew M.
    Thaci, Diamant
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2024, 25 (03) : 485 - 496
  • [33] Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
    Jonathan I. Silverberg
    Melinda J. Gooderham
    Amy S. Paller
    Mette Deleuran
    Christopher G. Bunick
    Linda F. Stein Gold
    DirkJan Hijnen
    Brian M. Calimlim
    Wan-Ju Lee
    Henrique D. Teixeira
    Xiaofei Hu
    Shiyu Zhang
    Yang Yang
    Ayman Grada
    Andrew M. Platt
    Diamant Thaçi
    American Journal of Clinical Dermatology, 2024, 25 : 485 - 496
  • [34] Characterization of haematological and transaminase laboratory findings associated with upadacitinib use in moderate-to-severe atopic dermatitis: results of two phase III Trials (Measure Up 1 and 2)
    Silverberg, J. I.
    Gooderham, M. J.
    de Bruin-Weller, M. S.
    Papp, K. A.
    Aoki, V.
    Paller, A. S.
    Ofori, S.
    Tenorio, A. R.
    Liu, Y.
    Liu, J.
    Chovatiya, Raj
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E168 - E169
  • [35] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, Eric L.
    de Bruin-Weller, Marjolein S.
    Prajapati, Vimal H.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Zeng, Jiewei
    Liu, Meng
    Silverberg, Jonathan I.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB60 - AB60
  • [36] Effects of upadacitinib on the patient-reported impact of atopic dermatitis: Atopic Dermatitis Impact Scale (ADerm-IS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Simpson, E. L.
    De Bruin-Weller, M. S.
    Prajapati, V. H.
    Calimlim, B. M.
    Teixeira, H. D.
    Zeng, J.
    Liu, M.
    Silverberg, J. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E124
  • [37] Improvement in Itch, Symptoms, and Quality of Life With Upadacitinib Through Week 16 in Adults and Adolescents With Atopic Dermatitis: Results From Phase 3 Studies (Measure Up 1, Measure Up 2, and AD Up)
    Lio, Peter
    Eichenfield, Lawrence F.
    Marcoux, Danielle
    Lee, Wan-Ju
    Teixeira, Henrique D.
    Raymundo, Eliza M.
    Gamelli, Amy E.
    Grada, Ayman
    Hu, Xiaofei
    Irvine, Alan D.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB178 - AB178
  • [38] EFFECT OF UPADACITINIB ON INTENSITY OF SCORAD ITEMS AND IMPACTS TO ITCH AND SLEEP: ANALYSIS FROM THE MEASURE UP 1 AND MEASURE UP 2 STUDIES
    Cameron, Michael
    Magnolo, Nina
    Prajapati, Vimal H.
    Haque, Adel
    Lee, Wan-Ju
    Altman, Katherine
    Platt, Andrew M.
    Lane, Michael C.
    Calimlim, Brian M.
    Taieb, Alain
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 56 - 57
  • [39] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) - results from two pivotal phase III studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, J. I.
    Thyssen, J. P.
    Rosmarin, D.
    Pink, A. E.
    Calimlim, B. M.
    Teixeira, H. D.
    Hu, X.
    Yang, Y.
    Thaci, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E124 - E125
  • [40] Effects of upadacitinib on patient-reported symptoms of atopic dermatitis: Atopic Dermatitis Symptom Scale (ADerm-SS) results from two pivotal phase 3 studies (MEASURE UP 1 and MEASURE UP 2)
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Rosmarin, David
    Pink, Andrew E.
    Calimlim, Brian M.
    Teixeira, Henrique D.
    Hu, Xiaofei
    Yang, Yang
    Thaci, Diamant
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB7 - AB7
12345